Royal Bank of Canada
BCRX icon

Royal Bank of Canada’s BioCryst Pharmaceuticals BCRX Stock Holding History

Royal Bank of Canada’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$173K Sell
18,115
-143,341
-89% -$1.11M ﹤0.01% 4788
2025
Q4 		$1.26M Sell
161,456
-23,959
-13% -$173K ﹤0.01% 3488
2025
Q3 		$1.41M Sell
185,415
-37,175
-17% -$310K ﹤0.01% 3698
2025
Q2 		$1.99M Buy
222,590
+159,127
+251% +$1.48M ﹤0.01% 3306
2025
Q1 		$476K Buy
63,463
+1,458
+2% +$11.8K ﹤0.01% 4049
2024
Q4 		$466K Sell
62,005
-4,551
-7% -$34.5K ﹤0.01% 4138
2024
Q3 		$506K Sell
66,556
-10,266
-13% -$78K ﹤0.01% 4087
2024
Q2 		$475K Sell
76,822
-43,440
-36% -$240K ﹤0.01% 4054
2024
Q1 		$611K Buy
120,262
+6,739
+6% +$37.9K ﹤0.01% 3823
2023
Q4 		$680K Buy
113,523
+55,882
+97% +$324K ﹤0.01% 3992
2023
Q3 		$408K Buy
57,641
+13,397
+30% +$96.3K ﹤0.01% 4215
2023
Q2 		$312K Sell
44,244
-27,900
-39% -$224K ﹤0.01% 4347
2023
Q1 		$602K Sell
72,144
-12,690
-15% -$122K ﹤0.01% 3719
2022
Q4 		$974K Buy
84,834
+58,125
+218% +$725K ﹤0.01% 3527
2022
Q3 		$337K Sell
26,709
-54,843
-67% -$706K ﹤0.01% 4336
2022
Q2 		$863K Buy
81,552
+29,973
+58% +$309K ﹤0.01% 3636
2022
Q1 		$839K Sell
51,579
-27,375
-35% -$439K ﹤0.01% 3813
2021
Q4 		$1.09M Buy
78,954
+21,322
+37% +$282K ﹤0.01% 3713
2021
Q3 		$829K Buy
57,632
+22,037
+62% +$348K ﹤0.01% 3885
2021
Q2 		$563K Sell
35,595
-7,189
-17% -$97.7K ﹤0.01% 4165
2021
Q1 		$435K Buy
42,784
+11,727
+38% +$121K ﹤0.01% 4306
2020
Q4 		$231K Sell
31,057
-4,453
-13% -$23K ﹤0.01% 4756
2020
Q3 		$122K Buy
35,510
+20,351
+134% +$87.2K ﹤0.01% 4864
2020
Q2 		$72K Sell
15,159
-35,826
-70% -$143K ﹤0.01% 5034
2020
Q1 		$102K Buy
50,985
+45,261
+791% +$125K ﹤0.01% 4764
2019
Q4 		$20K Buy
5,724
+1,872
+49% +$4.71K ﹤0.01% 5844
2019
Q3 		$11K Buy
3,852
+1,699
+79% +$5.29K ﹤0.01% 5738
2019
Q2 		$8K Sell
2,153
-4,784
-69% -$28.8K ﹤0.01% 6089
2019
Q1 		$56K Buy
6,937
+2,442
+54% +$20.9K ﹤0.01% 5100
2018
Q4 		$36K Sell
4,495
-2,950
-40% -$22.9K ﹤0.01% 5270
2018
Q3 		$56K Buy
7,445
+7,032
+1,703% +$47.2K ﹤0.01% 5178
2018
Q2 		$3K Sell
413
-1,587
-79% -$8.74K ﹤0.01% 6151
2018
Q1 		$10K Buy
2,000
+894
+81% +$4.59K ﹤0.01% 5707
2017
Q4 		$5K Sell
1,106
-6,614
-86% -$32K ﹤0.01% 6065
2017
Q3 		$41K Buy
7,720
+7,259
+1,575% +$37.2K ﹤0.01% 5530
2017
Q2 		$3K Sell
461
-3,071
-87% -$18.7K ﹤0.01% 6176
2017
Q1 		$30K Sell
3,532
-596
-14% -$4.15K ﹤0.01% 5409
2016
Q4 		$26K Buy
4,128
+4,085
+9,500% +$21.3K ﹤0.01% 5615
2016
Q3 		$0 Buy
+43
New +$172 ﹤0.01% 6389
2016
Q2 		– Sell
-300
Closed -$1K – 6355
2016
Q1 		$1K Sell
300
-1,211
-80% -$5.37K ﹤0.01% 6196
2015
Q4 		$15K Sell
1,511
-1,819
-55% -$18.1K ﹤0.01% 5825
2015
Q3 		$38K Buy
3,330
+2,930
+733% +$39.1K ﹤0.01% 5274
2015
Q2 		$5K Buy
400
+100
+33% +$1.14K ﹤0.01% 6232
2015
Q1 		$3K Buy
+300
New +$3.11K ﹤0.01% 5837
2014
Q3 		– Sell
-3,500
Closed -$45K – 5965
2014
Q2 		$45K Hold
3,500
– – ﹤0.01% 4893
2014
Q1 		$37K Buy
+3,500
New +$37.3K ﹤0.01% 4976

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Royal Bank of Canada's BCRX Position: Q1 2026 in Review

Royal Bank of Canada reduced its BioCryst Pharmaceuticals (BCRX) stake by 89% in Q1 2026, selling an estimated $1.11M and leaving 18,115 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #4788.

Royal Bank of Canada first reported a position in BCRX in Q1 2014 and has held it in 46 quarters since. The position peaked at $1.99M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Royal Bank of Canada held 18,115 shares of BioCryst Pharmaceuticals worth $173K as of Q1 2026.
  • Royal Bank of Canada sold 143,341 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $1.11M.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #4788 holding.
  • Royal Bank of Canada first reported a position in BioCryst Pharmaceuticals in Q1 2014 and has held it in 46 quarters since.
  • Royal Bank of Canada's BioCryst Pharmaceuticals position peaked at $1.99M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.